David Wallace

Fresenius and Formycon have celebrated simultaneous US and EU approvals for the firms' partnered Otulfi ustekinumab rival to Stelara. And with competing biosimilars already available on the European market, all eyes will soon be on US launches at the start of 2025, with Fresenius providing a significant update on launch timing.

Organon and Henlius have marked progress on their partnered HLX11 pertuzumab candidate, with the proposed biosimilar to Perjeta meeting the primary endpoint in a Phase III trial.

As Sandoz publishes a report on US drug shortages – dissecting their root causes, the current policy landscape and recommendations for future improvements – the firm's North America head and AAM chair Keren Haruvi speaks to Generics Bulletin about what can be done to alleviate continuing supply-chain failures.

Aeon Biopharma has heralded its latest interaction with the US FDA over its planned Botox biosimilar as a win that sets the stage for analytical studies, trials and a subsequent filing.

Aspire Pharma has bolstered its dermatology portfolio by striking a deal to acquire “all assets” of another UK-based player, Canute Pharma.

Biocon Biologics chief commercial officer for advanced markets Matt Erick says the firm is a “quiet giant” in the biosimilars space, but speaks up about the firm's plans to grow its business in Europe, explore in-licensing as well as in-house development, and capitalize on the upcoming loss of exclusivity for Stelara in the US.

As Sandoz publishes a report on US drug shortages, including a call for policy and other improvements, the firm’s North America head and AAM Chair Keren Haruvi discussed potential solutions to ongoing supply-chain failures.

Sandoz, Adalvo and Eurofarma were the biggest winners at the Global Generics & Biosimilars Awards 2024, each taking multiple honors, among the many champions named across 14 separate categories at our prizegiving ceremony in Milan.

September saw the extreme price rises of the last few months subside in the UK, albeit still seeing a handful of treble-digit percentage average increases for products like telmisartan.

Disputes between shareholders of a corporation, and shareholders and their corporation, are stressful and complicated, and often attract (negative) publicity. Regardless of the outcome, any such dispute irreparably harms the reputations of all involved – including the corporation. But there are strategies to avoid such disputes or if not, then to resolve them without going to arbitration or litigation. Here’s a look at the duties of shareholders to the corporation and to each other, and eight strategies to avoid or resolve shareholder disputes.